ritonavir	fluvastatin	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	fluvastatin	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	fluvastatin	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	fluvastatin	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	paclitaxel	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	56946	D019438	56946
ritonavir	paclitaxel	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	56946	D019438	56946
ritonavir	paclitaxel	6	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	56946	D019438	56946
ritonavir	paclitaxel	6	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	56946	D019438	56946
ritonavir	nortriptyline	17	19	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		85762	none	D019438	none
ritonavir	nortriptyline	17	19	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		85762	none	D019438	none
ritonavir	pravastatin	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	pravastatin	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	pravastatin	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	pravastatin	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	repaglinide	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	73044	D019438	73044
ritonavir	repaglinide	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	73044	D019438	73044
ritonavir	repaglinide	6	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	73044	D019438	73044
ritonavir	repaglinide	6	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	73044	D019438	73044
ritonavir	dapsone	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	dapsone	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	dapsone	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	dapsone	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	atazanavir	17	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	none	D019438	none
ritonavir	atazanavir	17	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	none	D019438	none
ritonavir	atazanavir	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	atazanavir	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	atazanavir	17	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	none	D019438	none
ritonavir	atazanavir	17	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	none	D019438	none
ritonavir	atazanavir	16	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		85762	none	D019438	none
ritonavir	atazanavir	16	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		85762	none	D019438	none
ritonavir	atazanavir	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	atazanavir	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	atazanavir	16	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		85762	none	D019438	none
ritonavir	atazanavir	16	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		85762	none	D019438	none
ritonavir	atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	none	D019438	none
ritonavir	atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	none	D019438	none
ritonavir	atazanavir	6	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	none	D019438	none
ritonavir	atazanavir	6	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	none	D019438	none
ritonavir	atazanavir	8	10	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	none	D019438	none
ritonavir	atazanavir	8	10	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	none	D019438	none
ritonavir	atazanavir	9	10	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	none	D019438	none
ritonavir	atazanavir	9	10	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	none	D019438	none
ritonavir	atazanavir	9	11	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		85762	none	D019438	none
ritonavir	atazanavir	9	11	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		85762	none	D019438	none
ritonavir	REYATAZ	17	19	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		85762	0	D019438	382467
ritonavir	REYATAZ	17	19	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		85762	0	D019438	382467
ritonavir	REYATAZ	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	0	D019438	382467
ritonavir	REYATAZ	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	0	D019438	382467
ritonavir	REYATAZ	17	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	0	D019438	382467
ritonavir	REYATAZ	17	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	0	D019438	382467
ritonavir	REYATAZ	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	0	D019438	382467
ritonavir	REYATAZ	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	0	D019438	382467
ritonavir	REYATAZ	16	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		85762	0	D019438	382467
ritonavir	REYATAZ	16	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		85762	0	D019438	382467
ritonavir	REYATAZ	5	3	false	none	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	0	D019438	382467
ritonavir	REYATAZ	5	3	false	none	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	0	D019438	382467
ritonavir	REYATAZ	5	5	false	none	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	0	D019438	382467
ritonavir	REYATAZ	5	5	false	none	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	0	D019438	382467
ritonavir	REYATAZ	5	6	false	none	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	0	D019438	382467
ritonavir	REYATAZ	5	6	false	none	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	0	D019438	382467
ritonavir	REYATAZ	6	5	false	none	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	0	D019438	382467
ritonavir	REYATAZ	6	5	false	none	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	0	D019438	382467
ritonavir	REYATAZ	6	6	false	none	When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	0	D019438	382467
ritonavir	REYATAZ	6	6	false	none	When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	0	D019438	382467
ritonavir	REYATAZ	6	8	false	none	When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  [See Clinical Pharmacology, Table 14 (12.3).]  The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  		85762	0	D019438	382467
ritonavir	REYATAZ	6	8	false	none	When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  [See Clinical Pharmacology, Table 14 (12.3).]  The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  		85762	0	D019438	382467
ritonavir	REYATAZ	8	6	false	none	When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  [See Clinical Pharmacology, Table 14 (12.3).]  The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  		85762	0	D019438	382467
ritonavir	REYATAZ	8	6	false	none	When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  [See Clinical Pharmacology, Table 14 (12.3).]  The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  		85762	0	D019438	382467
ritonavir	REYATAZ	8	8	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  		85762	0	D019438	382467
ritonavir	REYATAZ	8	8	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  		85762	0	D019438	382467
ritonavir	REYATAZ	8	10	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	0	D019438	382467
ritonavir	REYATAZ	8	10	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	0	D019438	382467
ritonavir	REYATAZ	9	8	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  		85762	0	D019438	382467
ritonavir	REYATAZ	9	8	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  		85762	0	D019438	382467
ritonavir	REYATAZ	9	10	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	0	D019438	382467
ritonavir	REYATAZ	9	10	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	0	D019438	382467
ritonavir	desipramine	17	19	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		85762	none	D019438	none
ritonavir	desipramine	17	19	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		85762	none	D019438	none
ritonavir	erythromycin	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	erythromycin	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	erythromycin	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	erythromycin	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	metoprolol	17	19	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		85762	none	D019438	none
ritonavir	metoprolol	17	19	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		85762	none	D019438	none
ritonavir	azithromycin	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	azithromycin	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	azithromycin	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	azithromycin	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	Atazanavir	17	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	343047	D019438	343047
ritonavir	Atazanavir	17	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	343047	D019438	343047
ritonavir	Atazanavir	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	343047	D019438	343047
ritonavir	Atazanavir	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	343047	D019438	343047
ritonavir	Atazanavir	17	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	343047	D019438	343047
ritonavir	Atazanavir	17	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	343047	D019438	343047
ritonavir	Atazanavir	16	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		85762	343047	D019438	343047
ritonavir	Atazanavir	16	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		85762	343047	D019438	343047
ritonavir	Atazanavir	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	343047	D019438	343047
ritonavir	Atazanavir	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	343047	D019438	343047
ritonavir	Atazanavir	16	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		85762	343047	D019438	343047
ritonavir	Atazanavir	16	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		85762	343047	D019438	343047
ritonavir	Atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	343047	D019438	343047
ritonavir	Atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		85762	343047	D019438	343047
ritonavir	Atazanavir	6	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	343047	D019438	343047
ritonavir	Atazanavir	6	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		85762	343047	D019438	343047
ritonavir	Atazanavir	8	10	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	343047	D019438	343047
ritonavir	Atazanavir	8	10	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	343047	D019438	343047
ritonavir	Atazanavir	9	10	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	343047	D019438	343047
ritonavir	Atazanavir	9	10	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		85762	343047	D019438	343047
ritonavir	Atazanavir	9	11	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		85762	343047	D019438	343047
ritonavir	Atazanavir	9	11	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		85762	343047	D019438	343047
ritonavir	NORVIR	17	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	17	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	16	17	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	16	17	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	8	9	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	8	9	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	9	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  		85762	0	D019438	196479
ritonavir	NORVIR	9	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  		85762	0	D019438	196479
ritonavir	atazanavir sulfate	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	atazanavir sulfate	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	atazanavir sulfate	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
ritonavir	atazanavir sulfate	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		85762	none	D019438	none
fluvastatin	fluconazole	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluvastatin	nortriptyline	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
fluvastatin	acetaminophen	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluvastatin	pravastatin	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
fluvastatin	dapsone	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
fluvastatin	atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
fluvastatin	atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
fluvastatin	REYATAZ	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
fluvastatin	REYATAZ	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
fluvastatin	REYATAZ	18	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	382467
fluvastatin	REYATAZ	18	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	382467
fluvastatin	REYATAZ	18	20	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
fluvastatin	REYATAZ	18	20	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
fluvastatin	desipramine	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
fluvastatin	erythromycin	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
fluvastatin	methadone	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluvastatin	metoprolol	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
fluvastatin	azithromycin	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
fluvastatin	atenolol	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluvastatin	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
fluvastatin	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
fluvastatin	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
fluvastatin	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
fluvastatin	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
fluvastatin	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
fluvastatin	atazanavir sulfate	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
fluconazole	nortriptyline	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	acetaminophen	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	pravastatin	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	dapsone	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	REYATAZ	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
fluconazole	REYATAZ	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
fluconazole	REYATAZ	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
fluconazole	REYATAZ	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
fluconazole	REYATAZ	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
fluconazole	REYATAZ	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
fluconazole	desipramine	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	erythromycin	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	methadone	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	metoprolol	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	azithromycin	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	atenolol	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
fluconazole	Atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	343047	none	343047
fluconazole	Atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	343047	none	343047
fluconazole	atazanavir sulfate	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
paclitaxel	repaglinide	5	5	false	none	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		56946	73044	56946	73044
paclitaxel	repaglinide	5	5	false	none	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		56946	73044	56946	73044
paclitaxel	atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		56946	none	56946	none
paclitaxel	atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		56946	none	56946	none
paclitaxel	REYATAZ	5	3	true	positive	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		56946	0	56946	382467
paclitaxel	REYATAZ	5	3	true	positive	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		56946	0	56946	382467
paclitaxel	REYATAZ	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		56946	0	56946	382467
paclitaxel	REYATAZ	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		56946	0	56946	382467
paclitaxel	REYATAZ	5	6	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		56946	0	56946	382467
paclitaxel	REYATAZ	5	6	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		56946	0	56946	382467
paclitaxel	Atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		56946	343047	56946	343047
paclitaxel	Atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		56946	343047	56946	343047
nortriptyline	acetaminophen	19	20	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
nortriptyline	pravastatin	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
nortriptyline	dapsone	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
nortriptyline	atazanavir	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
nortriptyline	REYATAZ	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
nortriptyline	REYATAZ	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
nortriptyline	REYATAZ	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
nortriptyline	REYATAZ	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
nortriptyline	REYATAZ	19	20	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
nortriptyline	REYATAZ	19	20	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
nortriptyline	desipramine	19	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
nortriptyline	erythromycin	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
nortriptyline	methadone	19	20	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
nortriptyline	metoprolol	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
nortriptyline	azithromycin	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
nortriptyline	atenolol	19	20	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
nortriptyline	Atazanavir	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	343047	none	343047
nortriptyline	Atazanavir	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	343047	none	343047
nortriptyline	NORVIR	19	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	196479
nortriptyline	NORVIR	19	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	196479
nortriptyline	atazanavir sulfate	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
acetaminophen	pravastatin	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
acetaminophen	dapsone	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
acetaminophen	atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
acetaminophen	REYATAZ	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
acetaminophen	REYATAZ	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
acetaminophen	REYATAZ	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
acetaminophen	REYATAZ	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
acetaminophen	REYATAZ	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
acetaminophen	REYATAZ	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
acetaminophen	desipramine	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
acetaminophen	erythromycin	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
acetaminophen	methadone	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
acetaminophen	metoprolol	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
acetaminophen	azithromycin	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
acetaminophen	atenolol	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
acetaminophen	Atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	343047	none	343047
acetaminophen	Atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	343047	none	343047
acetaminophen	atazanavir sulfate	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
pravastatin	dapsone	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
pravastatin	atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
pravastatin	atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
pravastatin	REYATAZ	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
pravastatin	REYATAZ	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
pravastatin	REYATAZ	18	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	382467
pravastatin	REYATAZ	18	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	382467
pravastatin	REYATAZ	18	20	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
pravastatin	REYATAZ	18	20	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
pravastatin	desipramine	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
pravastatin	erythromycin	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
pravastatin	methadone	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
pravastatin	metoprolol	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
pravastatin	azithromycin	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
pravastatin	atenolol	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
pravastatin	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
pravastatin	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
pravastatin	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
pravastatin	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
pravastatin	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
pravastatin	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
pravastatin	atazanavir sulfate	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
repaglinide	atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		73044	none	73044	none
repaglinide	atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		73044	none	73044	none
repaglinide	REYATAZ	5	3	true	positive	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		73044	0	73044	382467
repaglinide	REYATAZ	5	3	true	positive	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		73044	0	73044	382467
repaglinide	REYATAZ	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		73044	0	73044	382467
repaglinide	REYATAZ	5	5	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		73044	0	73044	382467
repaglinide	REYATAZ	5	6	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		73044	0	73044	382467
repaglinide	REYATAZ	5	6	true	positive	Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		73044	0	73044	382467
repaglinide	Atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		73044	343047	73044	343047
repaglinide	Atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		73044	343047	73044	343047
dapsone	atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
dapsone	atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
dapsone	REYATAZ	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
dapsone	REYATAZ	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
dapsone	REYATAZ	18	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	382467
dapsone	REYATAZ	18	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	382467
dapsone	REYATAZ	18	20	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
dapsone	REYATAZ	18	20	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
dapsone	desipramine	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
dapsone	erythromycin	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
dapsone	methadone	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
dapsone	metoprolol	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
dapsone	azithromycin	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
dapsone	atenolol	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
dapsone	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
dapsone	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
dapsone	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
dapsone	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
dapsone	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
dapsone	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
dapsone	atazanavir sulfate	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
atazanavir	REYATAZ	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	382467
atazanavir	REYATAZ	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	382467
atazanavir	REYATAZ	16	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		none	0	none	382467
atazanavir	REYATAZ	16	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		none	0	none	382467
atazanavir	REYATAZ	2	2	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  		none	0	none	382467
atazanavir	REYATAZ	2	2	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  		none	0	none	382467
atazanavir	REYATAZ	2	3	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  		none	0	none	382467
atazanavir	REYATAZ	2	3	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  		none	0	none	382467
atazanavir	REYATAZ	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
atazanavir	REYATAZ	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	382467
atazanavir	REYATAZ	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	382467
atazanavir	REYATAZ	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	382467
atazanavir	REYATAZ	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
atazanavir	REYATAZ	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	0	none	382467
atazanavir	REYATAZ	4	2	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  		none	0	none	382467
atazanavir	REYATAZ	4	2	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  		none	0	none	382467
atazanavir	REYATAZ	4	3	false	none	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  		none	0	none	382467
atazanavir	REYATAZ	4	3	false	none	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  		none	0	none	382467
atazanavir	REYATAZ	4	5	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		none	0	none	382467
atazanavir	REYATAZ	4	5	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		none	0	none	382467
atazanavir	REYATAZ	4	6	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		none	0	none	382467
atazanavir	REYATAZ	4	6	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		none	0	none	382467
atazanavir	REYATAZ	10	8	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		none	0	none	382467
atazanavir	REYATAZ	10	8	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		none	0	none	382467
atazanavir	REYATAZ	10	10	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		none	0	none	382467
atazanavir	REYATAZ	10	10	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		none	0	none	382467
atazanavir	REYATAZ	11	10	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		none	0	none	382467
atazanavir	REYATAZ	11	10	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		none	0	none	382467
atazanavir	REYATAZ	11	13	false	none	Atazanavir solubility decreases as pH increases.  Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  		none	0	none	382467
atazanavir	REYATAZ	11	13	false	none	Atazanavir solubility decreases as pH increases.  Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  		none	0	none	382467
atazanavir	REYATAZ	12	10	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  		none	0	none	382467
atazanavir	REYATAZ	12	10	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  		none	0	none	382467
atazanavir	REYATAZ	12	13	false	none	Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  		none	0	none	382467
atazanavir	REYATAZ	12	13	false	none	Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  		none	0	none	382467
atazanavir	REYATAZ	15	13	false	none	7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.  7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  		none	0	none	382467
atazanavir	REYATAZ	15	13	false	none	7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.  7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  		none	0	none	382467
atazanavir	REYATAZ	15	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  		none	0	none	382467
atazanavir	REYATAZ	15	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  		none	0	none	382467
atazanavir	desipramine	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
atazanavir	erythromycin	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
atazanavir	erythromycin	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
atazanavir	methadone	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
atazanavir	metoprolol	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
atazanavir	azithromycin	16	18	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
atazanavir	azithromycin	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
atazanavir	atenolol	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
atazanavir	NORVIR	16	17	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		none	0	none	196479
atazanavir	NORVIR	16	17	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		none	0	none	196479
atazanavir	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
atazanavir	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
atazanavir	NORVIR	10	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		none	0	none	196479
atazanavir	NORVIR	10	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		none	0	none	196479
atazanavir	NORVIR	11	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		none	0	none	196479
atazanavir	NORVIR	11	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		none	0	none	196479
atazanavir	NORVIR	15	17	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		none	0	none	196479
atazanavir	NORVIR	15	17	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		none	0	none	196479
REYATAZ	desipramine	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	desipramine	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	desipramine	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	desipramine	18	19	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	desipramine	20	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	desipramine	20	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	erythromycin	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	erythromycin	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	erythromycin	18	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	none	382467	none
REYATAZ	erythromycin	18	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	none	382467	none
REYATAZ	erythromycin	20	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	erythromycin	20	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	methadone	19	20	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	methadone	19	20	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	methadone	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	methadone	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	methadone	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	methadone	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	metoprolol	19	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	metoprolol	19	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	metoprolol	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	metoprolol	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	metoprolol	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	metoprolol	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	azithromycin	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	azithromycin	19	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	azithromycin	18	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	none	382467	none
REYATAZ	azithromycin	18	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	none	382467	none
REYATAZ	azithromycin	20	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	azithromycin	20	18	true	negative	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	atenolol	19	20	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	atenolol	19	20	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	atenolol	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	atenolol	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	atenolol	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	atenolol	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	Atazanavir	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	343047	382467	343047
REYATAZ	Atazanavir	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	343047	382467	343047
REYATAZ	Atazanavir	2	2	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  		0	343047	382467	343047
REYATAZ	Atazanavir	2	2	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  		0	343047	382467	343047
REYATAZ	Atazanavir	2	4	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  		0	343047	382467	343047
REYATAZ	Atazanavir	2	4	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  		0	343047	382467	343047
REYATAZ	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	343047	382467	343047
REYATAZ	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	343047	382467	343047
REYATAZ	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	343047	382467	343047
REYATAZ	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	343047	382467	343047
REYATAZ	Atazanavir	3	2	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  		0	343047	382467	343047
REYATAZ	Atazanavir	3	2	false	none	7.1 Potential for REYATAZ to Affect Other Drugs    Atazanavir is an inhibitor of CYP3A and UGT1A1.  Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  		0	343047	382467	343047
REYATAZ	Atazanavir	3	4	false	none	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  		0	343047	382467	343047
REYATAZ	Atazanavir	3	4	false	none	Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.  Atazanavir is a weak inhibitor of CYP2C8.  		0	343047	382467	343047
REYATAZ	Atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	343047	382467	343047
REYATAZ	Atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	343047	382467	343047
REYATAZ	Atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		0	343047	382467	343047
REYATAZ	Atazanavir	5	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  		0	343047	382467	343047
REYATAZ	Atazanavir	6	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		0	343047	382467	343047
REYATAZ	Atazanavir	6	4	false	none	Atazanavir is a weak inhibitor of CYP2C8.  Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide).  When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected.  		0	343047	382467	343047
REYATAZ	Atazanavir	8	10	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		0	343047	382467	343047
REYATAZ	Atazanavir	8	10	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		0	343047	382467	343047
REYATAZ	Atazanavir	10	10	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		0	343047	382467	343047
REYATAZ	Atazanavir	10	10	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		0	343047	382467	343047
REYATAZ	Atazanavir	10	11	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		0	343047	382467	343047
REYATAZ	Atazanavir	10	11	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		0	343047	382467	343047
REYATAZ	Atazanavir	10	12	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  		0	343047	382467	343047
REYATAZ	Atazanavir	10	12	false	none	7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  		0	343047	382467	343047
REYATAZ	Atazanavir	13	11	false	none	Atazanavir solubility decreases as pH increases.  Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  		0	343047	382467	343047
REYATAZ	Atazanavir	13	11	false	none	Atazanavir solubility decreases as pH increases.  Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  		0	343047	382467	343047
REYATAZ	Atazanavir	13	12	false	none	Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  		0	343047	382467	343047
REYATAZ	Atazanavir	13	12	false	none	Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H2-receptor antagonists are administered with atazanavir.  7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  		0	343047	382467	343047
REYATAZ	Atazanavir	13	15	false	none	7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.  7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  		0	343047	382467	343047
REYATAZ	Atazanavir	13	15	false	none	7.3 Established and Other Potentially Significant Drug Interactions    Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ.  These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.  7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  		0	343047	382467	343047
REYATAZ	Atazanavir	15	16	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		0	343047	382467	343047
REYATAZ	Atazanavir	15	16	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  		0	343047	382467	343047
REYATAZ	Atazanavir	15	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  		0	343047	382467	343047
REYATAZ	Atazanavir	15	15	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  		0	343047	382467	343047
REYATAZ	NORVIR	19	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		382467	196479
REYATAZ	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		382467	196479
REYATAZ	NORVIR	8	9	false	none	The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered with ritonavir.  See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  		382467	196479
REYATAZ	NORVIR	10	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		382467	196479
REYATAZ	NORVIR	15	17	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		382467	196479
REYATAZ	atazanavir sulfate	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	atazanavir sulfate	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		0	none	382467	none
REYATAZ	atazanavir sulfate	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	none	382467	none
REYATAZ	atazanavir sulfate	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	none	382467	none
REYATAZ	atazanavir sulfate	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
REYATAZ	atazanavir sulfate	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		0	none	382467	none
desipramine	erythromycin	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
desipramine	methadone	19	20	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
desipramine	metoprolol	19	19	true	negative	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
desipramine	azithromycin	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
desipramine	atenolol	19	20	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
desipramine	Atazanavir	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	343047	none	343047
desipramine	Atazanavir	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	343047	none	343047
desipramine	NORVIR	19	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	196479
desipramine	NORVIR	19	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	196479
desipramine	atazanavir sulfate	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
erythromycin	methadone	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
erythromycin	metoprolol	18	19	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
erythromycin	azithromycin	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
erythromycin	atenolol	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
erythromycin	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
erythromycin	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
erythromycin	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
erythromycin	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
erythromycin	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
erythromycin	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
erythromycin	atazanavir sulfate	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
methadone	metoprolol	20	19	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
methadone	azithromycin	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
methadone	atenolol	20	20	false	none	Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
methadone	Atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	343047	none	343047
methadone	Atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	343047	none	343047
methadone	atazanavir sulfate	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
metoprolol	azithromycin	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
metoprolol	atenolol	19	20	false	none	REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
metoprolol	Atazanavir	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	343047	none	343047
metoprolol	Atazanavir	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	343047	none	343047
metoprolol	NORVIR	19	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	196479
metoprolol	NORVIR	19	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	0	none	196479
metoprolol	atazanavir sulfate	19	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  		none	none	none	none
azithromycin	atenolol	18	20	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
azithromycin	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
azithromycin	Atazanavir	18	16	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
azithromycin	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
azithromycin	Atazanavir	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	343047	none	343047
azithromycin	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
azithromycin	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	0	none	196479
azithromycin	atazanavir sulfate	18	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		none	none	none	none
atenolol	Atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	343047	none	343047
atenolol	Atazanavir	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	343047	none	343047
atenolol	atazanavir sulfate	20	18	false	none	Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol).  Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol.  		none	none	none	none
Atazanavir	NORVIR	16	17	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		343047	0	343047	196479
Atazanavir	NORVIR	16	17	false	none	Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		343047	0	343047	196479
Atazanavir	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		343047	0	343047	196479
Atazanavir	NORVIR	18	17	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		343047	0	343047	196479
Atazanavir	NORVIR	10	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		343047	0	343047	196479
Atazanavir	NORVIR	10	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  		343047	0	343047	196479
Atazanavir	NORVIR	11	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		343047	0	343047	196479
Atazanavir	NORVIR	11	9	false	none	See the complete prescribing information for NORVIR® (ritonavir) for information on drug interactions with ritonavir.  7.2 Potential for Other Drugs to Affect Atazanavir    Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZ’s therapeutic effect.  Atazanavir solubility decreases as pH increases.  		343047	0	343047	196479
Atazanavir	NORVIR	15	17	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		343047	0	343047	196479
Atazanavir	NORVIR	15	17	false	none	7.4 Drugs with No Observed or Predicted Interactions with REYATAZ    Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.  Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.  See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  		343047	0	343047	196479
NORVIR	atazanavir sulfate	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	none	196479	none
NORVIR	atazanavir sulfate	17	18	false	none	See the complete prescribing information for NORVIR® for information on other potential drug interactions with ritonavir.  Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  		0	none	196479	none
